August 31, 2011 -- Royal DSM, the Dutch life sciences and materials company, and Sinochem received regulatory approval for their antibiotic JV. The JV, announced last December, called for Sinochem to buy a 50% stake in DSM’s anti-infectives unit for a price of $291 million. The JV combines DSM’s expertise in anti-infective APIs with Sinochem’s experience in China marketing. The JV will be headquartered in Hong Kong. More details....
Stock Symbol: (XAMS: DSM)
